Dual-target Bridging ELISA for Bispecific Antibodies
- 29 September 2022
- journal article
- research article
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 12 (19)
Abstract
An open platform for life scientists to share, find,and discuss research protocolsKeywords
This publication has 10 references indexed in Scilit:
- PD‐L1/TIGIT bispecific antibody showed survival advantage in animal modelClinical and Translational Medicine, 2022
- HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activitiesClinical and Translational Medicine, 2022
- Antibodies to watch in 2022mAbs, 2022
- A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacyJournal of Biological Chemistry, 2021
- Bioassay Development for Bispecific Antibodies—Challenges and OpportunitiesInternational Journal of Molecular Sciences, 2021
- A bispecific IgG format containing four independent antigen binding sitesScientific Reports, 2020
- Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343Clinical Cancer Research, 2019
- A Regulatory Perspective on Testing of Biological Activity of Complex BiologicsTrends in Biotechnology, 2018
- “Two-in-One” approach for bioassay selection for dual specificity antibodiesJournal of Immunological Methods, 2017
- Dual targeting strategies with bispecific antibodiesmAbs, 2012